N-Arachidonoyl Dopamine-d8 – 1 mg

Brand:
Cayman
CAS:
1159908-42-5
Storage:
-20
UN-No:
De Minimis - 1170 / 3

N-Arachidonoyl dopamine-d8 contains eight deuterium atoms at the 5, 6, 8, 9, 11, 12, 14, and 15 positions. It is intended for use as an internal standard for the quantification of N-arachidonoyl dopamine by GC- or LC-mass spectrometry. Several different arachidonoyl amino acids, including NADA, have been isolated and characterized from bovine brain.{9589} NADA is the amide of the neurotransmitter dopamine and arachidonic acid. NADA is a CB1-selective cannabinoid agonist, inducing the typical tetrad of hypothermia, analgesia, catalepsy, and hypomotility in rats which exceeds that of anandamide (AEA).{9213} NADA is a full agonist at the vanilloid receptor 1, but is inactive on the dopaminergic D1 and D2 receptors. NADA is also a potent inhibitor (IC50 = 0.25 µM) of the proliferation of MCF-7 breast carcinoma cells. Recent reports of NADA’s endothelium-dependent vasodilation indicate that some of its cannabinergic activities antagonized by SR141716A may be non-CB1/CB2 dependent.{11224}  

 

Available on backorder

SKU: 10007431 - 1 mg Category:

Description

An internal standard for the quantification of N-arachidonoyl dopamine by GC- or LC-MS.


Formal name: N-[2-(3,4-dihydroxyphenyl)ethyl]-5Z,8Z,11Z,14Z-eicosatetraenamide-5,6,8,9,11,12,14,15-d8

Synonyms:  NADA-d8

Molecular weight: 447.6

CAS: 1159908-42-5

Purity: ≥99% deuterated forms (d1-d8)

Formulation: A solution in ethanol


Application|Mass Spectrometry||Product Type|Biochemicals|Analytical Standards||Product Type|Biochemicals|Isotopically Labeled Standards|Deuterium||Product Type|Biochemicals|Lipids|Fatty Amides||Research Area|Cancer||Research Area|Lipid Biochemistry|Endocannabinoid/Endocannabinoid-like||Research Area|Neuroscience|Cannabinoid Research|CB1 & CB2 Receptors||Research Area|Neuroscience|Pain Research